학술논문
PND37 - The Cost-Effectiveness of Daclizumab Beta Vs Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis Patients With Inadequate Response To Prior Treatment In Scotland
Document Type
Abstract
Author
Source
In Value in Health October-November 2017 20(9):A723-A724
Subject
Language
ISSN
1098-3015